Lincotek Receives FDA Clearance for SportLinc Ankle Stabilization Device, Targets Orthopedic OEM Market
Key Insights
Lincotek (search) has obtained FDA 510(k) clearance for its SportLinc Syndesmosis Device (search), a sterile implant designed to stabilize ankle syndesmosis injuries commonly known as high ankle sprains.
The device features ultra-high-molecular-weight polyethylene suture between two titanium alloy buttons and arrives preloaded in a sterile inserter with complete surgical toolkit.
SportLinc is positioned as an OEM platform available for private labeling and can serve as a predicate device to accelerate regulatory pathways for orthopedic partners.
Lincotek (search) has secured FDA 510(k) clearance (K252081) for its SportLinc Syndesmosis Device (search), marking a significant milestone for the company's Medical Division as it positions the sterile, single-use implant for commercial deployment with orthopedic OEM partners. The device is engineered to stabilize syndesmotic trauma of the ankle, addressing a common injury in sports medicine and trauma care.
Device Design and Clinical Application
The SportLinc device features an ultra-high-molecular-weight polyethylene (UHMWPE) suture tensioned between two low-profile titanium alloy buttons. The assembly arrives preloaded in a sterile inserter instrument, designed to reduce preparation steps and support efficiency in both hospital and Ambulatory Surgery Center settings.
The system is supplied as a complete, single-use package that includes a drill, drill guide, and tension handles, consolidating the surgical toolkit and reducing operational complexity for care teams. The device offers surgeons flexibility as it can be used either alongside plate fixation or as a standalone solution, depending on the severity and nature of the injury.
SportLinc targets syndesmosis injuries, commonly known as high ankle sprains, which involve damage to the ligaments connecting the tibia (search) and fibula (search) above the ankle joint (search). These injuries are typically caused by forced external rotation of the foot and are frequently encountered in sports trauma and ankle fracture (search) cases.
Strategic OEM Platform
Beyond its clinical application, Lincotek (search) is positioning SportLinc as a platform for orthopedic industry partners. The device is available for private labeling and can serve as a predicate device, allowing OEM customers to accelerate regulatory pathways and shorten the timeline from concept to market entry.
"We pride ourselves on helping customers bring products to market in less than one year from the design concept to the 510k approval, keeping them ahead in an increasingly competitive industry," said Francesco Bucciotti, Head of Global Business and Business Development at Lincotek (search)'s Medical Division. "SportLinc has big commercial potential and will have a strong appeal to clinicians dealing with sports injuries. With FDA clearance in place, we're now ready to provide a market-ready solution to orthopedic OEMs."
Troy Walters, Product Development Director, emphasized the device's design philosophy: "SportLinc was developed with a focus on balancing strength, flexibility, and ease of use – three elements that are essential in modern orthopedic surgery. It reflects the expertise and dedication of the Lincotek (search) product development team in supporting orthopedic OEMs with continuously innovative solutions."
Market Expansion Plans
With U.S. clearance secured, Lincotek (search) is now pursuing CE Mark certification to extend SportLinc's reach into European markets, broadening the device's commercial footprint and reinforcing the company's strategy of supporting orthopedic OEMs across major regulatory jurisdictions.
The FDA clearance represents part of a broader trend in the additive manufacturing medical device space, where 510(k) clearances have become strategic differentiators and commercial platforms. Companies increasingly pursue clearances not only for the devices themselves, but to establish predicate status and license cleared processes to OEM partners, compressing time-to-market for related products.